Cognition Therapeutics (CGTX) Stock Forecast & Price Target

$0.45 0.00 (0.00%)

(As of 12/17/2024 ET)

Cognition Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 6 Analyst Ratings

Sell
0

Hold
2

Buy
4

Based on 6 Wall Street analysts who have issued ratings for Cognition Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 2 have given a hold rating, and 4 have given a buy rating for CGTX.

Consensus Price Target

$8.00
1,658.63% Upside

According to the 6 analysts' twelve-month price targets for Cognition Therapeutics, the average price target is $8.00. The highest price target for CGTX is $14.00, while the lowest price target for CGTX is $1.00. The average price target represents a forecasted upside of 1,658.63% from the current price of $0.45.

Get the Latest News and Ratings for CGTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cognition Therapeutics and its competitors.

CGTX Analyst Ratings Over Time

Type	Current Forecast 12/19/23 to 12/18/24	1 Month Ago 11/19/23 to 11/18/24	3 Months Ago 9/20/23 to 9/19/24	1 Year Ago 12/19/22 to 12/19/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	1 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$8.00	$8.00	$8.00	$6.00
Forecasted Upside	1,658.63% Upside	1,628.98% Upside	1,212.77% Upside	224.32% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Do this Before Elon’s Reveal on January 22nd (Ad)

Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.

I urge you to watch this video now.

CGTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CGTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cognition Therapeutics Stock vs. The Competition

Type	Cognition Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	1,658.63% Upside	28,675.54% Upside	12.02% Upside
News Sentiment Rating	Neutral News See Recent CGTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/27/2024	HC Wainwright 2 of 5 stars	R. Selvaraju Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00	+1,136.07%
11/15/2024	Chardan Capital 1 of 5 stars	D. Gataulin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00	+2,285.03%
8/6/2024	B. Riley 4 of 5 stars	M. Mamtani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$5.00 ➝ $1.00	+54.92%
7/30/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Duncan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/2/2024	Rodman & Renshaw Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00	+669.23%
3/27/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$9.00	+391.80%
8/14/2023	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$10.00 ➝ $6.00	+275.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:42 AM ET.

CGTX Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Cognition Therapeutics is $8.00, with a high forecast of $14.00 and a low forecast of $1.00.
: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cognition Therapeutics in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CGTX shares.
: According to analysts, Cognition Therapeutics's stock has a predicted upside of 1,658.63% based on their 12-month stock forecasts.
: Cognition Therapeutics has been rated by research analysts at Chardan Capital, and HC Wainwright in the past 90 days.
: Analysts like Cognition Therapeutics less than other "medical" companies. The consensus rating score for Cognition Therapeutics is 2.67 while the average consensus rating score for "medical" companies is 2.81. Learn more on how CGTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This drone stock is setting up to transform medical supply delivery (Ad)

Drone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.

Click here to see how a new partnership could catapult this drone suppliers' growth

This page (NASDAQ:CGTX) was last updated on 12/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cognition Therapeutics (CGTX) Stock Forecast & Price Target